Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Romain MarignierJeffrey L BennettHo Jin KimBrian G WeinshenkerSean J PittockDean WingerchukKazuko FujiharaFriedemann PaulGary R CutterAri J GreenOrhan AktasHans-Peter HartungFred D LublinIan M WilliamsJorn DrappaDewei SheDaniel CimboraWilliam ReesMichael SmithJohn N RatchfordEliezer KatzBruce A C Creenull nullPublished in: Neurology(R) neuroimmunology & neuroinflammation (2021)
This study provides Class II evidence that for patients with NMOSD, inebilizumab reduces the risk of worsening disability. N-MOmentum is registered at ClinicalTrials.gov: NCT02200770.